Literature DB >> 1787185

Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin.

M Tomita1, W Bellamy, M Takase, K Yamauchi, H Wakabayashi, K Kawase.   

Abstract

The antibacterial properties of enzymatic hydrolysates of bovine lactoferrin were examined to determine whether active peptides are produced from this protein. Hydrolysates prepared by cleavage of lactoferrin with porcine pepsin, cod pepsin, or acid protease from Penicillium duponti showed strong activity against Escherichia coli O111, whereas hydrolysates produced by trypsin, papain, or other neutral proteases were much less active. Low molecular weight peptides generated by porcine pepsin cleavage of lactoferrin showed broad-spectrum antibacterial activity, inhibiting the growth of a number of Gram-negative and Gram-positive species, including strains that were resistant to native lactoferrin. The antibacterial potency of the hydrolysate was at least eightfold greater than that of undigested lactoferrin with all strains tested. The active peptides retained their activity in the presence of added iron, unlike native lactoferrin. The effect of the hydrolysate was bactericidal as indicated by a rapid loss of viability of E. coli O111. The lactoferrin hydrolysate described in the present study has commercial value as a natural preservative agent for use in foods and cosmetics, and as a functional component of new clinical foods for prevention or treatment of gastrointestinal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787185     DOI: 10.3168/jds.S0022-0302(91)78608-6

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  52 in total

1.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 2.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

3.  Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin.

Authors:  Shaper Mirza; Landon Wilson; William H Benjamin; Jan Novak; Stephen Barnes; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

4.  Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice.

Authors:  M L Kruzel; Y Harari; C Y Chen; G A Castro
Journal:  Inflammation       Date:  2000-02       Impact factor: 4.092

Review 5.  Immune components of colostrum and milk--a historical perspective.

Authors:  Thomas T Wheeler; Alison J Hodgkinson; Colin G Prosser; Stephen R Davis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-11-09       Impact factor: 2.673

Review 6.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 7.  Bioactive peptides and proteins from foods: indication for health effects.

Authors:  Niels Peter Möller; Katharina Elisabeth Scholz-Ahrens; Nils Roos; Jürgen Schrezenmeir
Journal:  Eur J Nutr       Date:  2008-05-27       Impact factor: 5.614

8.  Hydrolytic breakdown of lactoferricin by lactic acid bacteria.

Authors:  Moushumi Paul; George A Somkuti
Journal:  J Ind Microbiol Biotechnol       Date:  2009-11-19       Impact factor: 3.346

Review 9.  Lactoferrin as a natural immune modulator.

Authors:  Jeffrey K Actor; Shen-An Hwang; Marian L Kruzel
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Glycans of bovine lactoferrin function as receptors for the type 1 fimbrial lectin of Escherichia coli.

Authors:  S Teraguchi; K Shin; Y Fukuwatari; S Shimamura
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.